GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
NCT ID: NCT00089856
Last Updated: 2008-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
626 participants
INTERVENTIONAL
2004-07-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Standard of care - chemotherapy
Chemotherapy (Taxotere and prednisone)
Chemotherapy (Taxotere and prednisone)
1
Immunotherapy
Immunotherapy with allogeneic prostate vaccine
Immunotherapy with allogeneic prostate vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunotherapy with allogeneic prostate vaccine
Immunotherapy with allogeneic prostate vaccine
Chemotherapy (Taxotere and prednisone)
Chemotherapy (Taxotere and prednisone)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
* Detectable metastases
* Any Gleason score
* ECOG performance status 0-2
Exclusion Criteria
* Prior Immunotherapy
* Prior treatment with gene therapy
* Significant cancer related pain
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cell Genesys
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cell Genesys, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Alabama Oncology, LLC
Alabaster, Alabama, United States
Alaska Clinical Research Center
Anchorage, Alaska, United States
Palo Verde Hematology/Oncology
Glendale, Arizona, United States
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
ACRC/Arizona Clinical Res. Ctr. Inc.
Tuscon, Arizona, United States
Arkansas Cancer Research Center
Little Rock, Arkansas, United States
Compassionate Cancer Care Medical Group, Inc.
Corona, California, United States
Pacific Coast Hem Onc. Medical Group
Fountain Valley, California, United States
California Cancer Care
Greenbrae, California, United States
Center for Urological Research
La Mesa, California, United States
Oncology Care Medical Associates
Montebello, California, United States
UC Irvine Medical Center
Orange, California, United States
San Bernardino Urological Associates
San Bernardino, California, United States
Sharp Healthcare
San Diego, California, United States
California Pacific Medical Center
San Francisco, California, United States
Cancer Research & Prevention Center
Soquel, California, United States
San Diego Cancer Center
Vista, California, United States
Univ. of Colorado Health Science Center
Aurora, Colorado, United States
Cancer Center of Colorado Springs
Colorado Springs, Colorado, United States
The Hope Clinic
Bristol, Connecticut, United States
Urology Center of Grove Hill
New Britain, Connecticut, United States
Carl & Dorothy Bennett Cancer Center
Stamford, Connecticut, United States
Boca Raton Community Hospital, Inc.
Boca Raton, Florida, United States
Michael and Dianne Bienes Comprehensive Cancer Center, Holy Cross Hospital
Fort Lauderdale, Florida, United States
Integrated Community Oncology Network
Jacksonville, Florida, United States
Oncology-Hematology Group of South Florida/Advanced Medical Specialists
Miami, Florida, United States
Cancer Centers of Florida
Ocoee, Florida, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
Urology Consultants
Safety Harbor, Florida, United States
Atlanta VAMC
Atlanta, Georgia, United States
Georgia Cancer Specialists
Atlanta, Georgia, United States
Peachtree Hematology Oncology Consultants, PC
Atlanta, Georgia, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Central Georgia Cancer Care, P.C.
Macon, Georgia, United States
Straub Clinic & Hospital
Honolulu, Hawaii, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Welborn Clinic Research Center
Evansville, Indiana, United States
Fort Wayne Medical Oncology/Hematology Inc.
Fort Wayne, Indiana, United States
Louisiana Oncology Associates
Lafayette, Louisiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, United States
West Michigan Regional Cancer and Blood Center
Free Soil, Michigan, United States
William Beaumont Hospital, Cancer Clinical Trials Office
Royal Oak, Michigan, United States
Newland Medical Associates, P.C.
Southfield, Michigan, United States
Hematology Oncology Consultants, Inc.
St Louis, Missouri, United States
Deaconess Billings Clinic
Billings, Montana, United States
Hematology/Oncology Centers of the Northern Rockies, P.C.
Billings, Montana, United States
Omaha VA Medical Center
Omaha, Nebraska, United States
Omaha VA Medical Center
Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
The Center for Cancer & Hematologic Disease
Cherry Hill, New Jersey, United States
Hematology-Oncology Associates of Northern New Jersey
Morristown, New Jersey, United States
Summit Medical Group/Overlook Oncology Center
Summit, New Jersey, United States
Columbia University Medical Center
New York, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Jacobi Medical Center
The Bronx, New York, United States
Presbyterian Hospital/ Center for Cancer Research
Charlotte, North Carolina, United States
Northwestern Carolina Hematology Oncology, PA
Hickory, North Carolina, United States
Medcenter One Cancer Care / Odyssey Research
Bismarck, North Dakota, United States
Dakota Cancer Institute
Fargo, North Dakota, United States
Gabrail Cancer Center
Canton, Ohio, United States
Cleveland Clinic Foundation, Taussig Cancer Center
Cleveland, Ohio, United States
University of Oklahoma
Oklahoma City, Oklahoma, United States
Providence Portland Medical Center
Portland, Oregon, United States
Urologic Surgery PC
Bala-Cynwyd, Pennsylvania, United States
Medical Oncology Associates
Kingston, Pennsylvania, United States
Lancaster Cancer Center, Ltd
Lancaster, Pennsylvania, United States
Urological Associates of Lancaster
Lancaster, Pennsylvania, United States
University of Pittsburgh Cancer Center
Pittsburgh, Pennsylvania, United States
Charleston Hematology Oncology
Charleston, South Carolina, United States
Memorial Health Care System
Chattanooga, Tennessee, United States
The West Clinic
Memphis, Tennessee, United States
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, United States
Mary Crowley Medical Research Center
Dallas, Texas, United States
Center for Oncology Research and Treatment PA
Dallas, Texas, United States
Urology Specialists and Associates, P.A.
Dallas, Texas, United States
Mobley Research Center
Houston, Texas, United States
Urology San Antonio
San Antonio, Texas, United States
Tyler Cancer Center
Tyler, Texas, United States
Southwestern Oncology Research Department
Bennington, Vermont, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Virginia Mason Medical Center Urology
Seattle, Washington, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
ZNA Middelheim
Antwerp, , Belgium
Imelda Ziekenhuis
Bonheiden, , Belgium
University Hospital Antwerp (UZA)
Edegem, , Belgium
UZ Gent
Ghent, , Belgium
Unversity Hospial Gent
Ghent, , Belgium
Virga Jesse Ziekenhuis
Hasselt, , Belgium
AZ Groeninge
Kortrijk, , Belgium
Heilig Hartziekenhuis Roeselare Men
Roeselare, , Belgium
Regionaal Ziekenhuis Sint Trudo
Sint-Truiden, , Belgium
Princess Margaret Hospital
Toronto, Ontario, Canada
CHUM Notre-Dam
Montreal, Quebec, Canada
McGill University
Montreal, Quebec, Canada
Ultra Med Inc.
Pointe-Claire, Quebec, Canada
Centre Hopitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Centre Paul Papin
Angers, , France
Centre Francois Baclesse
Caen, , France
Centre Georges Francois Leclerc
Dijon, , France
Centre Leon Berard Service de Cancerologie Medicale
Lyon, , France
Institut Paoli-Calmettes
Marseille, , France
Centre Rene Gauducheau
Nantes-Saint Herblain, , France
Institut Jean Godinot
Reims, , France
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, , France
Universitatsklinikum Aachen Urologie
Aachen, , Germany
der Technischen Universitat Dresden
Dresden, , Germany
Universitatsklinik um Essen
Essen, , Germany
Universitatsklinik um des Saarlande
Homburg/Saar, , Germany
VU Medisch Centrum
Amsterdam, , Netherlands
University Medical Centre Groningen
Groningen, , Netherlands
University Hospital, Linkoping
Linköping, , Sweden
University Hospital Lund
Lund, , Sweden
Akademiska University Hospital
Uppsala, , Sweden
Addenbrooke's Hospital
Cambridge, , United Kingdom
Beatson Oncology Centre
Glasgow, , United Kingdom
St. James's University Hospital
Leeds, , United Kingdom
Hammersmith Hospital
London, , United Kingdom
Mount Vernon Hospital
Middlesex, , United Kingdom
Newcastle General Hospital
Newcastle upon Tyne, , United Kingdom
Northampton General Hosptial
Northampton, , United Kingdom
Nottingham City Hospital
Nottingham, , United Kingdom
Oxford Cancer Centre, Churchill Hospital
Oxford, , United Kingdom
Scunthorpe General Hospital
Scunthorpe, , United Kingdom
Royal Hallamshire Hospital
Sheffield, , United Kingdom
Glan Clwyd Hospital
Wales, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vuky J, Corman JM, Porter C, Olgac S, Auerbach E, Dahl K. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer. Oncologist. 2013 Jun;18(6):687-8. doi: 10.1634/theoncologist.2011-0234. Epub 2013 Jun 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
(VITAL-1)
Identifier Type: -
Identifier Source: secondary_id
G-0029
Identifier Type: -
Identifier Source: org_study_id